Floyd Brown says there are five pharmaceutical companies offering outstanding dividend yields in a growing sector. And with most negative sentiment already priced into the stocks, downside risk is limited…

Investing in biotech stocks can be incredibly rewarding, financially and personally, says Marc Lichtenfeld writing in Investment U. However, timing is crucial to success. Here, Marc walks investors through the three phases of the drug development process…

There has been a lot of strong recommendations around biotech lately on Contrarian Profits. Phase 1 Investor editor Rob Fannon recently wrote that biotech was one of the few market sectors to show positive returns as many other stocks were getting hammered. He sees great values in the sector.

If the deal does go through it may be bad news for Roche and Genentech shareholders, according to Phase 1 Investor editor Rob Fannon in The Growth Stock Wire. But it would be good news for the biotech industry as a whole…